<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02136030</url>
  </required_header>
  <id_info>
    <org_study_id>TTYLA0701</org_study_id>
    <nct_id>NCT02136030</nct_id>
  </id_info>
  <brief_title>Liposomal Amphotericin B for the Treatment of Cryptococcal Meningitis</brief_title>
  <official_title>A Randomized Study to Evaluate the Safety and Efficacy of Liposomal Amphotericin B and Amphotericin B Deoxycholate With or Without Flucytosine Followed by Fluconazole, for the Treatment of Cryptococcal Meningitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TTY Biopharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TTY Biopharm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of liposomal amphotericin B and amphotericin B
      deoxycholate with or without flucytosine followed by fluconazole for the treatment of
      cryptococcal meningitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects who meet all eligible requirements will be randomized into study group （Lipo-AB）or
      control group（Amphotericin B deoxycholate） in 2:1 ratio. Subjects will be treated with
      induction therapy in study group or in control group with flucytosine for at least 14 days,
      and followed by consolidation therapy for another 56 days after CSF sterilization.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>suscceful response rate</measure>
    <time_frame>Day 14</time_frame>
    <description>Successful response was defined as both satisfactory clinical and microbiological response at the completion of 14 days treatment period.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Cryptococcal Meningitis</condition>
  <arm_group>
    <arm_group_label>Lipo-AB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Amphotericin B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal amphotericin B</intervention_name>
    <description>4mg/kg/day, IV infusion</description>
    <arm_group_label>Lipo-AB</arm_group_label>
    <other_name>Lipo-AB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amphotericin B-deoxycholate</intervention_name>
    <description>1mg/kg/day, IV infusion</description>
    <arm_group_label>Amphotericin B</arm_group_label>
    <other_name>Amphotericin B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults with age of at least 18 years.

          2. Within 7 days prior to, or at the time of screening visit, patient with cryptococcus
             meningitis, diagnosed by :

               1. CSF India ink staining positive OR

               2. CSF cryptococcal antigen test positive OR

               3. CSF culture positive

          3. Patient or his/her legally acceptable representative has signed the written informed
             consent form.

        Exclusion Criteria:

          1. Patients have laboratory abnormalities within 3 days prior to screening visit :

               1. ALT &gt; 5x UNL,

               2. AST &gt; 5x UNL,

               3. Creatinine &gt; 2mg/dl

          2. Patient is pregnant or lactating.

          3. Patient participate other investigational drug trial within 1 month before entering
             this study.

          4. Patient has some indications that another systemic antifungal drug would be needed in
             addition to assigned drugs in study.

          5. Patient had contraindication of amphotericin B or azole.

          6. Patient is not available for lumbar puncture.

          7. Patient with life expectancy less than 5 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yee-chun Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yee-chun Chen, MD</last_name>
    <phone>886-2-2312-3456</phone>
    <phone_ext>65054</phone_ext>
    <email>yeechunchen@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Po-Liang Lu, MD</last_name>
    <phone>886-7-3121101</phone>
    <phone_ext>5675</phone_ext>
    <email>d830166@cc.kmc.edu.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://www.google.com/search?q=emome&amp;ie=utf-8&amp;oe=utf-8</url>
    <description>Clinical trials network in Taiwan</description>
  </link>
  <reference>
    <citation>Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010 Feb 1;50(3):291-322. doi: 10.1086/649858.</citation>
    <PMID>20047480</PMID>
  </reference>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2014</study_first_submitted>
  <study_first_submitted_qc>May 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2014</study_first_posted>
  <last_update_submitted>May 8, 2014</last_update_submitted>
  <last_update_submitted_qc>May 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cryptococcal meningitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Meningitis, Cryptococcal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
    <mesh_term>Amphotericin B, deoxycholate drug combination</mesh_term>
    <mesh_term>Deoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

